The objective of this study is to evaluate the efficacy of Sasch1, a novel anti-infective eyedrop, in the treatment of acute infectious conjunctivitis.

This is a Phase II single-center, double-masked, placebo controlled, randomized study of SCH1 for the treatment of infectious conjunctivitis. Approximately 30 subjects will be enrolled, who will be randomized in a 1:1 ratio between SCH1and placebo. Subjects will be assessed at day 1, day 3, and day 5 for efficacy and safety.

Inclusion Criteria:

• Conjunctivitis (as defined below) within 72 hours of initial ocular symptoms.
• At least 18 years of age.
• Subjects capable of understanding the purpose and risks of the study, and able to give informed consent.
• Conjunctivitis diagnosis defined as presence of the two cardinal signs of acute conjunctivitis- 1) bulbar conjunctival injection and 2) conjunctival discharge/exudates.
• A three-point rating scale (0=absent, 1=mild, 2=moderate, 3=severe) will be employed to grade conjunctival discharge/exudates.
• All patients will require a rating of 1(mild) or greater for conjunctival discharge/exudates.
• Patients will require a rating of 1 (mild) for bulbar conjunctival injection.

Exclusion Criteria:

• Conjunctivitis greater than 72 hours after initial ocular symptoms
• Corneal ulcer, endophthalmitis, or any other confounding infection of the eye
• Patients taking topical anti-inflammatory medications on a chronic basis
• Known steroid glaucoma responders
• Active herpes ocular infection
• Pregnant women
• Known allergy to chlorhexidine

5 days

Caveat: While designed to evaluate efficacy in any type of infectious conjunctivitis, the majority of patients recruited turned out to have viral conjunctivitis.